Dose-finding based on feasibility and late-onset toxicity in adoptive cell therapy trials

References

• Bagley, E. M., and N. A. Wages. 2022. Impact of dose feasibility on the conduct of Phase I trials of adoptive cell therapy. Contemporary Clinical Trials Communications 25:100877. doi:10.1016/j.conctc.2021.100877.
   PubMed Web of Science ®Google Scholar
• Cheung, Y. K. 2011. Dose finding by the continual reassessment method. In Chapman & Hall/CRC biostatistics series, 37. Boca Raton FL: Chapman & Hall.
   Google Scholar
• Cheung, K. C., and R. C. Chapell. 2000. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56 (4):1177–1182. doi:10.1111/j.0006-341X.2000.01177.x.
   PubMed Web of Science ®Google Scholar
• Conaway, M. R., and G. R. Petroni. 2019. The Impact of early-phase trial design in the drug development process. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 25 (2):819–827. doi:10.1158/1078-0432.CCR-18-0203.
   PubMed Web of Science ®Google Scholar
• Devlin, S. M., A. Iasonos, and J. O’Quigley. 2021. Phase I clinical trials in adoptive T-cell therapies. Journal of the Royal Statistical Society: Series C 70 (4):815–834. doi:10.1111/rssc.12485.
   Web of Science ®Google Scholar
• FDA center for biologics evaluation and research guidance. 2015. Accessible at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-early-phase-clinical-trials-cellular-and-gene-therapy-products
   Google Scholar
• Horton, B. J., N. A. Wages, and M. R. Conaway. 2019. Shift models for dose-finding in partially ordered groups. Clinical Trials 16 (1):32–40. doi:10.1177/1740774518801599.
   PubMed Web of Science ®Google Scholar
• Hu, B., B. N. Bekele, and Y. Ji. 2013. Adaptive dose insertion in early phase clinical trials. Clin Trials 10(2):216–224.
   PubMed Web of Science ®Google Scholar
• Lee, S. M., D. Backenroth, Y. K. Cheung, D. Hershman, D. Vulih, B. Anderson, P. Ivy, and L. Minasian. 2016. Case example of dose optimization using data from bortezomib dose-finding clinical trials. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 34 (12):1395–1401. PMCID: PMC5070578. doi:10.1200/JCO.2015.66.0662.
   PubMed Web of Science ®Google Scholar
• Lee, S. M., and Y. K. Cheung. 2009. Model calibration in the continual reassessment method. Clinical Trials 6 (3):227–238. doi:10.1177/1740774509105076.
   PubMed Web of Science ®Google Scholar
• Lee, S. M., and Y. K. Cheung. 2011. Calibration of prior variance in the bayesian continual reassessment method. Statistics in Medicine 30 (17):2081–2089. doi:10.1002/sim.4139.
   PubMed Web of Science ®Google Scholar
• Lee, D. W., J. N. Kochenderfer, M. Stetler-Stevenson, Y. K. Cui, C. Delbrook, S. A. Feldman, T. J. Fry, R. Orentas, M. Sabatino, N. N. Shah, et al. 2015. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: A phase I dose-escalation trial. The Lancet. 385(9967):517–528. doi:10.1016/S0140-6736(14)61403-3.
   PubMed Web of Science ®Google Scholar
• Lum, L. G., A. Thakur, Z. Al-Kadhimi, G. A. Colvin, F. J. Cummings, R. D. Legare, D. S. Dizon, N. Kouttab, A. Maizel, W. Colaiace, et al. 2015. Targeted T-cell Therapy in Stage IV Breast Cancer; a Phase I Clinical Trial. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 21 (10):2305–2314. PMID: 25688159; PMCID: PMC4433762. doi:10.1158/1078-0432.CCR-14-2280.
   PubMed Web of Science ®Google Scholar
• Lum, L. G., A. Thakur, Q. Liu, A. Deol, Z. Al-Kadhimi, L. Ayash, M. H. Abidi, C. Pray, E. N. Tomaszewski, P. A. Steele, et al. 2013. CD20 -targeted T cells after stem cell transplantation for high risk and refractory non -Hodgkin’s lymphoma. Biology of Blood and Marrow Transplantation 19 (6):925–933. PMID: 23529012; PMCID: PMC3794673. doi:10.1016/j.bbmt.2013.03.010.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., and A. Iasonos. 2014. Bridging solutions in dose finding problems. Statistics in Biopharmaceutical Research 6 (2):185–197. doi:10.1080/19466315.2014.906365.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., and X. Paoletti. 2003. Continual reassessment method for ordered groups. Biometrics 59 (2):430–440. doi:10.1111/1541-0420.00050.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., M. Pepe, and L. Fisher. 1990, Mar. Continual reassessment method: A practical design for phase 1 clinical trials in cancer. ( PMID: 2350571) Biometrics 46 (1):33–48. doi: 10.2307/2531628.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., L. Z. Shen, and A. Gamst. 1999. Two -sample continual reassessment method. Journal of Biopharmaceutical Statistics 9 (1):17–44. doi:10.1081/BIP-100100998.
   PubMedGoogle Scholar
• Piantadosi, S., J. D. Fisher, and S. Grossman. 1998. Practical implementation of a modified continual reassessment method for dose finding trials. Cancer Chemotherapy and Pharmacology 41:429–436.
   PubMed Web of Science ®Google Scholar
• Printz, C. 2015. Failure rate: Why many cancer drugs don’t receive FDA approval, and what can be done about it. Cancer 121 (10):1529–1530. PMID: 25946212. doi:10.1002/cncr.28994.
   PubMed Web of Science ®Google Scholar
• Roda, D., B. Jimenez, and U. Banerji. 2016. Are doses and schedules of small-molecule targeted anticancer drugs recommended by phase I studies realistic? Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 22 (9):2127–2132. PMID: 26581244. doi:10.1158/1078-0432.CCR-15-1855.
   PubMed Web of Science ®Google Scholar
• Sharon, E., M. Y. Polley, M. B. Bernstein, and M. Ahmed. 2014. Immunotherapy and radiation therapy: Considerations for successfully combining radiation into the paradigm of immuno-oncology drug development. Radiation Research 182(2):252–257.
   PubMed Web of Science ®Google Scholar
• Thall, P. F., H. -G. Sung, and A. Choudhury. 2001. Dose-finding based on feasibility and toxicity in T-cell infusion trials. Biometrics 57 (3):914–921. doi:10.1111/j.0006-341X.2001.00914.x.
   PubMed Web of Science ®Google Scholar
• Vaishampayan, U., A. Thakur, R. Rathore, N. Kouttab, and L. G. Lum. 2015. Phase I study of anti -CD3 x anti -her2 bispecific antibody in metastatic castrate resistant prostate cancer patients. Prostate Cancer 2015:285193. PMID: 25802762; PMCID: PMC4352947. doi:10.1155/2015/285193.
   PubMedGoogle Scholar
• Wages, N. A., and C. E. Fadul. 2020. Adaptive dose finding based on safety and feasibility in early phase clinical trials of adoptive cell immunotherapy. Clinical Trials 17 (2):157–165. doi:10.1177/1740774519890145.
   PubMed Web of Science ®Google Scholar
• Wages, N. A., P. W. Read, and G. R. Petroni. 2015. A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial. Pharmaceutical Statistics 14 (4):302–310.
   PubMed Web of Science ®Google Scholar
• Werkhoven, E., S. Hinsley, E. Frangou, J. Holmes, R. Haan, M. Hawkins, S. Brown, and S. Love. 2020. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples. BMC Medical Research Methodology 20 (162):1–10.
   Google Scholar
• Yu, J. X., S. Upadhaya, R. Tatake, F. Barkalow, and V. M. Hubbard-Lucey. 2020. Cancer cell therapies: The clinical trial landscape. Nature Reviews Drug Discovery 19 (9):583–584. ( PMID: 32457476).
   PubMed Web of Science ®Google Scholar